PALB2 and breast cancer: How cost-effective are ovarian and breast cancer risk reduction strategies among women with pathogenic variants in individual cancer susceptibility genes (ie, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BRIP1)?